Clinical Trial Update: MK2206 in Treating Patients With Advanced Refractory Biliary Cancer That Cannot Be Removed by Surgery [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating MK-2206 in patients with advanced biliary cancers (including hepatocellular carcinoma and gallbladder/extrahepatic cholangiocarcinomas)…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Distal Cholangiocarcinoma
• Extrahepatic Cholangiocarcinoma
• Gallbladder Cancer
• Hepatocellular Carcinoma

Drugs mentioned

• MK-2206 (MK-2206)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Adult Hepatocellular Carcinoma, Localized Non-Resectable Adult Liver Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2016-04-15